Drugs and Developing Countries
Last month, under heavy pressure, five big companies agreed to reduce their drug prices in Africa and other poor regions afflicted by AIDS. Is that enough? What about other diseases? And, with companies in business not for charity but for profit, how much can they be asked to contribute to the health of the world?